Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. (Q50876217)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 July 2017

Language	Label	Description	Also known as
English	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.	scientific article published on 19 July 2017

Statements

scholarly article

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/28734759

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

1 reference

based on heuristic

inferred from title

colorectal cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

DNA mismatch repair

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Heinz-Josef Lenz

5

object named as

Heinz-Josef Lenz

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

author name string

Michael J Overman

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Ray McDermott

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Joseph L Leach

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Michael A Morse

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Andrew Hill

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Michael Axelson

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Rebecca A Moss

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Monica V Goldberg

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Z Alexander Cao

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Jean-Marie Ledeine

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Gregory A Maglinte

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

publication date

19 July 2017

1 reference

Europe PubMed Central

24 March 2018

http://europepmc.org/abstract/MED/28734759

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

1182-1191

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

BRAF mutations in colorectal cancer: clinical relevance and role in targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of TAS-102 for refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930422-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28734759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/S1470-2045(17)30422-9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6207072&resulttype=core&format=json

12 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50876217&oldid=1802752396"